Logo Image
|Videos|June 16, 2020

The Value of COVID-19 Data Collection

Some countries have been proactive in patient logging and tracking. How can even retroactive assessment benefit future preventive responses?

One of the proactive failures of coronavirus 2019 (COVID-19) preparation was the delayed start to data collection. While precautions were made to equip hospitals and health systems with resources, personnel were re-allocated to at-need divisions, and telemedicine was greenlit by payers, little uniformity was practiced among states logging patients and disease spread.

It is now 3 months after the fact that investigators such as Pinar Karaca-Mandic, PhD, are stressing that clinicians learn from this shortcoming in future pandemic risks.

In the next segment of an interview with Contagion, Karaca-Mandic, Academic Director of the Medical Industry Leadership Institute at the University of Minnesota Carlson School of Management, discussed the found value of COVID-19 data in pandemic response—and what may have gone wrong back in March.

“Really, I think there’s going to be more and more effort and more and more need for data reporting, and we have the capability to do this,” she explained. “It’s just that maybe we were never asked to do this at such a large scale.”

Karaca-Mandic also discussed the variety of technology now available to help immediate clinicians, patients, public health officials, and payers stay connected.

“Some more proactive data collection, real-time data collection, and standardized data collection are needed,” she stressed.

Related to this article

View more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more
FAQ: Shamonda Virus
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more